Placental Macrophages Following Maternal SARS-CoV-2 Infection in Relation to Placental Pathology

• Published in: Frontiers in virology (online) Vol. 2
• Main Authors: Sharps, Megan C., Garrod, Ainslie, Aneni, Emmanuel, Jones, Carolyn J. P., Batra, Gauri, Heazell, Alexander E. P.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 08.02.2022
• Subjects: COVID-19; histopathology; macrophages; placenta; SARS-CoV-2
• ISSN: 2673-818X; 2673-818X
• DOI: 10.3389/fviro.2022.813312

Introduction In December 2019, a novel coronavirus, SARS-CoV-2, was identified. Whilst pregnant women appear to be at risk of severe infection, pre-term birth, and stillbirth, it is unclear whether placental dysfunction is a consistent feature of maternal SARS-CoV-2 infection during pregnancy. We aim to describe the immune response in placentas of women who had COVID-19 infection during pregnancy and investigate whether there are any associated morphological changes. Methods The placentas of women testing positive for COVID-19 during their pregnancy were compared to contemporaneous controls who were not known to have had COVID-19 during pregnancy. Samples of each placenta were sent for histopathological analysis or underwent immunohistochemical staining for CD163, CD20, CD3, CD31, and SARS-CoV-2 spike protein. A subset of samples were sent for transmission electron microscopy. Results There was a significant increase in the number of CD163 + macrophages in the Post COVID group (p = 0.0020). There was no difference in the percentage of CD3 + , CD20 + cells, but there was an increase in placental vascularity in the Post COVID group compared to controls (p = 0.026). There were no structural differences observed between the samples sent for EM analysis. However, one of the placentas from the Post COVID group was seen to have several large sub-apical vacuoles in the syncytiotrophoblast. We did not observe any virions within the vacuoles and SARS-CoV-2 spike protein staining was negative for the sample. Histopathological investigations indicated that there was no specific placental pathology caused by maternal COVID-19 infection in this cohort of samples. Conclusions This study did not confirm previous studies which describe a possible increase in cases of both maternal and fetal vascular malperfusion, and placentitis in women who had COVID-19, which were seen in association with adverse pregnancy outcomes. It remains unclear whether observed abnormalities are caused by maternal infection, or whether maternal infection exacerbates existing placental pathology; understanding why some placentas generate these abnormalities is a key goal.